3,5-二甲氧基吡啶-4-胺 | 900804-00-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3,5-二甲氧基吡啶-4-胺
• 英文名称: 3,5-dimethoxypyridin-4-amine
• CAS: 900804-00-4
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD03425883
• 分子量: 154.169
• InChiKey: WGTFHDOGITXBBS-UHFFFAOYSA-N

物化性质

• 沸点：
  309.1±37.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  57.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  3,5-二氯-4-氰基吡啶 在 硫酸 、 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 10.0h， 生成 3,5-二甲氧基吡啶-4-胺
  参考文献：
  名称：

  WO2020073011A5

  摘要：

  公开号：

  WO2020073011A5

文献信息

• [EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2020144638A1

  公开（公告）日：2020-07-16

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.

  揭示了一种通过调节DHODH来治疗受影响的疾病、疾病或医疗状况的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1a、R1b、R2和R3在此处定义。
• COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY
  申请人：Annapurna Bio Inc.

  公开号：EP3860998A1

  公开（公告）日：2021-08-11
• DIHYDROOROTATE DEHYDROGENASE INHIBITORS
  申请人：Janssen Biotech, Inc.

  公开号：EP3908579A1

  公开（公告）日：2021-11-17
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DU RÉCEPTEUR DE L'APJ
  申请人：ANNAPURNA BIO INC

  公开号：WO2020073011A1

  公开（公告）日：2020-04-09

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.
• WO2020073011A5
  申请人：——

  公开号：WO2020073011A5

  公开（公告）日：2022-10-12